Literature DB >> 20376081

Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease.

E Terpos1, J Berenson, R J Cook, A Lipton, R E Coleman.   

Abstract

Skeletal-related events (SREs) are common in patients with osteolytic lesions from multiple myeloma (MM), and result in substantial morbidity. We report herein a comprehensive, retrospective, multivariate analysis of prognostic factors for survival and first on-study SRE in MM patients using data from the phase III, randomized study comparing zoledronic acid with pamidronate in MM or breast cancer. Cox regression analyses were used to assess 22 variables for prognostic significance (defined as associations with P<0.05) in patients with bone metabolism marker assessments and complete baseline variable data. Of 510 evaluable MM patients, 282 had complete covariate information and were included in models. Reduced Cox multivariate models identified five significant prognostic factors for first SRE (weight, race, high N-terminal cross-linked telopeptide of type I collagen (NTX), high pain score, and need for narcotic analgesics) and seven for survival (age, SRE history, myeloma subtype, anemia, high lactate dehydrogenase, high NTX, and low albumin levels). High NTX was the only variable associated with elevated risks of both first SRE and death (P< or =0.02 for each). These analyses identified prognostic factors for SREs and survival in patients with MM. Taken together with current staging systems, these factors could further facilitate decision making for optimal treatment of myeloma bone disease, although further prospective assessments are needed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20376081     DOI: 10.1038/leu.2010.62

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  30 in total

Review 1.  Osteonecrosis of the jaw and bisphosphonates in cancer: a narrative review.

Authors:  Cesar A Migliorati; Joel B Epstein; Elliot Abt; James R Berenson
Journal:  Nat Rev Endocrinol       Date:  2010-11-16       Impact factor: 43.330

Review 2.  The role of positron emission tomography-computed tomography and magnetic resonance imaging in diagnosis and follow up of multiple myeloma.

Authors:  Jo Caers; Nadia Withofs; Jens Hillengass; Paolo Simoni; Elena Zamagni; Roland Hustinx; Yves Beguin
Journal:  Haematologica       Date:  2014-04       Impact factor: 9.941

3.  Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma.

Authors:  Kevin W Song; Meletios A Dimopoulos; Katja C Weisel; Philippe Moreau; Antonio Palumbo; Andrew Belch; Stephen Schey; Pieter Sonneveld; Lars Sternas; Xin Yu; Ramesh Amatya; Mara S Monzini; Mohamed Zaki; Christian Jacques; Jesus San Miguel
Journal:  Haematologica       Date:  2014-11-25       Impact factor: 9.941

4.  Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study.

Authors:  Evangelos Terpos; Noopur Raje; Peter Croucher; Ramon Garcia-Sanz; Xavier Leleu; Waltraud Pasteiner; Yang Wang; Anthony Glennane; Jude Canon; Charlotte Pawlyn
Journal:  Blood Adv       Date:  2021-02-09

Review 5.  Bone disease in multiple myeloma and precursor disease: novel diagnostic approaches and implications on clinical management.

Authors:  Sigurdur Y Kristinsson; Alex R Minter; Neha Korde; Esther Tan; Ola Landgren
Journal:  Expert Rev Mol Diagn       Date:  2011-07       Impact factor: 5.225

Review 6.  Bisphosphonates in multiple myeloma: an updated network meta-analysis.

Authors:  Rahul Mhaskar; Ambuj Kumar; Branko Miladinovic; Benjamin Djulbegovic
Journal:  Cochrane Database Syst Rev       Date:  2017-12-18

7.  Iterative decomposition of water and fat with echo asymmetry and least-squares estimation (IDEAL) imaging of multiple myeloma: initial clinical efficiency results.

Authors:  Miyuki Takasu; Chihiro Tani; Yasuko Sakoda; Miho Ishikawa; Keizo Tanitame; Shuji Date; Yuji Akiyama; Akira Sakai; Hideki Asaoku; Toshio Kajima; Kazuo Awai
Journal:  Eur Radiol       Date:  2011-12-04       Impact factor: 5.315

8.  Mechanisms of multiple myeloma bone disease.

Authors:  Deborah L Galson; Rebecca Silbermann; G David Roodman
Journal:  Bonekey Rep       Date:  2012-08-01

9.  Circulating cytokines present in multiple myeloma patients inhibit the osteoblastic differentiation of adipose stem cells.

Authors:  Michèle Sabbah; Laurent Garderet; Ladan Kobari; Martine Auclair; Olivier Piau; Nathalie Ferrand; Maurice Zaoui; François Delhommeau; Bruno Fève
Journal:  Leukemia       Date:  2021-09-23       Impact factor: 11.528

10.  Melphalan flufenamide inhibits osteoclastogenesis by suppressing proliferation of monocytes.

Authors:  Konstantin Byrgazov; Thomas Lind; Annica J Rasmusson; Claes Andersson; Ana Slipicevic; Fredrik Lehmann; Joachim Gullbo; Håkan Melhus; Rolf Larsson; Mårten Fryknäs
Journal:  Bone Rep       Date:  2021-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.